On September 9, 2026 Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, reported positive updated data as of the August 18, 2026 data cutoff date from its ongoing global Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The updated results represent a population (N=33 efficacy evaluable) dosed at 5.4 mg/kg intravenously once every three weeks with a dose equivalent to or below a dose cap. These data demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR). Median progression-free survival (mPFS) was 6.2 months, and the 12-month overall survival (OS) probability was 79% while median OS (mOS) has not yet been reached. Clinical activity was observed across key patient subgroups, including HPV status and prior treatment. No new safety signals were observed (N=35 safety evaluable), and dose capping reduced the frequency and severity of adverse events in high body weight patients.

MICVO, the company’s lead program, is a first-in-concept antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix. MICVO’s differentiated, non-EGFR targeting mechanism of action positions it to potentially serve a significant patient population and address unmet need in 2L+ R/M HNSCC as the first-line treatment landscape continues to evolve.

"There remains significant need for effective treatment options for patients with recurrent or metastatic head and neck cancer who progress following first-line therapy, particularly as the front-line treatment landscape continues to evolve," said Alan L. Ho, M.D., Ph.D., Chief, Head and Neck Oncology Service and Attending Medical Oncologist, Memorial Sloan Kettering Cancer Center. "In this heavily pretreated population, these results demonstrated rapid and deep responses, along with progression-free survival and preliminary overall survival results that warrant further evaluation."

"These updated data reinforce our conviction in MICVO’s potential to become an important treatment option for patients with cancer," said Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology. "We are particularly encouraged by the combination of rapid and deep responses, substantial survival outcomes and a manageable safety profile. The data also provide important validation of our dose capping strategy, which was intended to maintain clinical activity while mitigating the risk of safety events. Based on feedback from the FDA and EMA on the design of our pivotal Phase 3 study, Headliner, we believe MICVO is well positioned for success in a randomized trial, which we plan to initiate in mid-2027."

Updated MICVO Phase 1 Monotherapy Trial Results as of August 18, 2026

Demographics
Table 1: Patient Demographics and Disease Characteristics – 5.4 mg/kg Dose Cap Population (N=35)

Table 1: Patient Demographics and Disease Characteristics – 5.4 mg/kg Dose Cap Population (N=35)

Data as of 18-Aug-2026
1. cetuximab: Eli Lilly and Company & Merck KGaA; petosemtamab: Genmab A/S; ficerafusp alpha: Bicara Therapeutics
Abbreviations: HPV: human papillomavirus; SCC: squamous cell carcinoma; EGFR: epidermal growth factor receptor; IO: immuno-oncology; ECOG: Eastern Cooperative Oncology Group; BMI: body mass index; PR: partial response; N/n: number of patients.

Efficacy Data
Table 2: Efficacy Data Summary – 5.4 mg/kg Dose Cap Efficacy-Evaluable Population (N=33)

Efficacy Measure 5.4 mg/kg Dose Cap
(N=33)
Confirmed objective response rate (cORR), % (n/N) 36% (12/33)
Disease control rate (DCR), % (n/N) 94% (31/33)
Responders achieving response by the first scan at six weeks, % 75%
Responders achieving >50% tumor reduction from baseline*, % 83%
Median progression-free survival (mPFS), months, (95% CI) 6.2 (4.8-8.8)
12-month overall survival (OS) probability, %, (95% CI) 79% (58.1,90.3)
Median overall survival (OS), months NR (NR-NR)
Data as of 18-Aug-2026
*Per RECIST v1.1
Abbreviations: n/N: number of patients.

Table 3: Efficacy Data Across Key Patient Subgroups

Patient Subgroup N 5.4 mg/kg Dose Cap
Confirmed ORR, % 5.4 mg/kg Dose Cap
Median PFS, months
HPV Status
HPV+ oropharyngeal 17 35%
6.2
HPV-unrelated 16 38%
5.9
Prior EGFRi
Yes 18 28%
5.0
No 15 47%
8.8
Prior Novel EGFRi*
Yes 5 40%
5.8
Prior Taxane
Yes 23 35%
6.2
No 10 40%
4.9
Data as of 18-Aug-2026
*Prior novel EGFRi subgroup is a subset of patients with prior EGFRi treatment.
Abbreviations: HPV: human papillomavirus; ORR: objective response rate; EGFRi: EGFR inhibitor; n/N: number of patients.

Safety Data
No new safety signals were observed with MICVO. The tolerability data was consistent with that of other ADCs with auristatin payloads and was generally manageable. Adverse events of interest, including peripheral neuropathy, generally occurred after patients had received evidence of benefit, and after prolonged duration of treatment.

Table 4: Safety Data Summary – 5.4 mg/kg Dose Cap Population (N=35)

TRAEs 5.4 mg/kg with Dose Cap
(N=35)
Treatment duration – median days (range) 120 (21-470)
All TRAEs, n (%) 32 (91.4%)
TRAEs of CTCAE Grade ≥ 3, n (%) 19 (54.3%)
Non-Hematologic TRAEs of CTCAE Grade ≥ 3, n (%) 15 (42.9%)
Serious TRAEs, n (%) 5 (14.3%)
TRAEs leading to treatment discontinuation*, n (%) 5 (14.3%)
TRAEs leading to treatment discontinuation days, median (min-max) 162 (104-212)
TRAEs leading to dose reduction, n (%) 14 (40.0%)
Treatment related deaths (Grade 5) 0
ADC Payload TRAEs of Interest 5.4 mg/kg with Dose Cap
(N=35)

Gr1/2 Gr3
Cutaneous, n (%) 17 (48.6%) 2 (5.7%)
Peripheral Neuropathy, n (%) 14 (40.0%) 6 (17.1%)
Peripheral Neuropathy days to onset, median (min-max) 82 (3-151) 166 (85-197)
Ocular, n (%) 10 (28.6%) 2 (5.7%)
Pneumonitis, n (%) 4 (11.4%) 0
Data as of 18-Aug-2026
*TRAEs leading to discontinuation, N=1 Ocular, N=1 Muscle Weakness, N=3 Peripheral Neuropathy
Abbreviations: ADC: antibody-drug conjugate; TRAE: treatment-related adverse event; CTCAE: Common Terminology Criteria for Adverse Events; Gr: grade; N: number of patients.

MICVO Next Steps

Monotherapy
Pyxis Oncology is advancing the clinical development of MICVO through Project Optimus, a U.S. Food and Drug Administration (FDA) initiative focused on dose optimization and dose selection in oncology drug development. An End of Phase 2 meeting with the FDA to align on dose selection is anticipated in the first quarter of 2027. Updated overall survival data from the MICVO monotherapy study are expected in the first half of 2027.

The Company has aligned with the feedback from the FDA and the European Medicines Agency (EMA) on the design of the planned pivotal Phase 3 monotherapy study of MICVO in patients with second- or third-line R/M HNSCC who have progressed following treatment with both a platinum-based therapy and an anti-PD-1 therapy. The randomized, open-label, 2-arm study will enroll approximately 500 patients who will be randomized 1:1 to receive MICVO or investigators’ choice of cetuximab, docetaxel, or methotrexate. The co-primary endpoints of the study will be overall response rate and overall survival. Pyxis Oncology plans to initiate the study in mid-2027 following alignment with the FDA on dose selection.

Combination with KEYTRUDA (pembrolizumab)
Pyxis Oncology expects to report updated data from the ongoing Phase 1/2 combination dose escalation study of MICVO and Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy KEYTRUDA (pembrolizumab) for 1L R/M HNSCC patients in the fourth quarter of 2026. Preliminary positive results for the treatment of 1L/2L+ R/M HNSCC were shared in December 2025. Additional data evaluating initial durability and selection of the recommended Phase 3 dose (RP3D) for the 1L combination are expected in the second half of 2027.

Webcast Information
Pyxis Oncology will host a live webcast today at 7:30 a.m. Eastern Time. To participate in the live event, please register using this link. The event and accompanying slides can be accessed by visiting the investor relations section of the Company’s website at View Source An archived webcast will be available on the Company’s website following the event.

About the MICVO Phase 1 Monotherapy Trial
The ongoing Phase 1 monotherapy study of MICVO is a multi-part study. Part 1 was a dose escalation study across multiple doses and tumor types, with initial results shared in November 2024. Part 2 is a dose expansion study in 2L+ R/M HNSCC. Preliminary Phase 1 study results in 2L+ R/M HNSCC were shared in December 2025.

The dose expansion portion of the study includes two arms: post-platinum and anti-PD-(L)1 patients (Arm 1) and post-EGFR inhibitor and anti-PD-(L)1 patients (Arm 2). Target enrollment for each arm was approximately 20 patients, and the Company completed target enrollment in the Phase 1 Part 2 monotherapy dose expansion study in the first quarter of 2026.

In December 2025, a dose cap was implemented for high body weight patients. Based on internal pharmacokinetic (PK) simulation modeling indicating that MICVO exposures with dose capping and adjusted ideal bodyweight (AIBW) dosing are expected to be comparable, dose capping was prioritized due to its operational simplicity and speed of implementation. The updated results reported today focus on patients treated at 5.4 mg/kg Q3W with a dose cap.

About Micvotabart Pelidotin (MICVO)
Micvotabart pelidotin (MICVO, formerly PYX-201) is an antibody-drug conjugate (ADC) that uniquely targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix. MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extra-cellular matrix density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response.

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)-1 therapy.

(Press release, Pyxis Oncology, SEP 9, 2026, View Source [SID1234670706])

On September 9, 2026 Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, reported positive data from the Phase 1 imaging trial designed to evaluate the safety, biodistribution and dosimetry of RAD 301 in healthy volunteers and subjects with Pancreatic Ductal Adenocarcinoma (PDAC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RAD301 is a peptide-based molecule bound to Gallium-68 (Ga-68) that targets αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas. The αvβ6-integrin receptor is found in high density on most pancreatic carcinoma cells, making it an attractive diagnostic and therapeutic target. RAD 301 has previously received Orphan Drug Designation (ODD) from the FDA.

"These data are an important step forward for patients suffering from advanced pancreatic cancer, as RAD301 has demonstrated significant and selective tumor uptake in metastatic lesions," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "Given the limited imaging and treatment options available for patients with PDAC, these findings highlight the potential role of RAD301 in improving disease detection, patient selection, and future theranostic applications. Pancreatic cancer remains a challenging disease to image, and conventional approaches such as FDG PET are limited by variable tumor biology and non-specific uptake. The results from this Phase 1 study support the potential of αvβ6-integrin-targeted imaging to provide a more tumor-specific approach to detecting pancreatic cancer, further supporting the advancement of RAD 301 into Phase 2 development."

Data from the Phase 1 trial of RAD301 demonstrated a favorable safety profile in all evaluable participants. Additionally, RAD301 had favorable biodistribution along with significant tumor uptake in pancreatic cancer metastases, consistent with initial results from the first five patients evaluated. The results showed significant and selective tumor uptake in pancreatic cancer metastases, which supports the potential of αvβ6-integrin as a target for future therapeutic development and potentially as a theranostic pair. Importantly, the low background uptake observed in liver, lung and bowel — the sites where pancreatic cancer most often spreads — supports the potential of RAD301 to distinguish metastatic lesions from surrounding normal tissue. The unmet medical need in the earlier stages of disease and the high mortality of the disease provide a rationale for a future Phase 2 imaging trial of RAD301.

(Press release, Radiopharm Theranostics, SEP 9, 2026, View Source [SID1234670705])

On September 9, 2026 Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company, focused on developing novel therapies for high-impact, difficult-to-treat cancers, reported new preclinical data evaluating elraglusib in combination with zoldonrasib (RMC-9805), an investigational RAS(ON) G12D-selective inhibitor, and daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, in pancreatic ductal adenocarcinoma (PDAC), including models resistant to FOLFIRINOX chemotherapy. The studies were conducted in collaboration with investigators at Northwestern University and the Mayo Clinic.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Across a panel of murine KPC pancreatic cancer cell lines, the addition of elraglusib to zoldonrasib resulted in greater inhibition of tumor-cell growth compared with zoldonrasib alone. Synergistic combination activity was also observed across human patient-derived xenograft (PDX)-derived pancreatic cancer cell lines, demonstrating the effect across multiple independent pancreatic cancer models. Studies of elraglusib in combination with daraxonrasib were also conducted, demonstrating synergistic anti-cancer activity compared with either agent alone. Together, the findings with two distinct RAS-targeted agents provide evidence that the combination effect of elraglusib extends beyond a single RAS inhibitor.

"The emergence of direct RAS inhibitors represents a major advance in pancreatic cancer and creates an opportunity to identify combinations capable of further enhancing RAS-directed activity," said Tanios "Tony" Bekaii-Saab, MD, FASCO – Chair for the Division of Hematology/Medical Oncology, Mayo Clinic in Arizona. "Importantly, the enhanced activity observed when elraglusib was combined with either zoldonrasib or daraxonrasib, two distinct RAS-targeted agents, highlights the potential for elraglusib to synergize with diverse RAS-directed therapies. Based on the unique and complementary mechanisms of action of elraglusib with these new RAS inhibition therapies, we are eager to evaluate the potential of combining elraglusib with RAS inhibition therapies in a clinical setting to expand treatment opportunities across RAS-driven diseases, including pancreatic cancer."

Separate studies evaluated the combination of elraglusib with zoldonrasib in FOLFIRINOX-resistant murine and human pancreatic cancer models. Both murine and human models demonstrated that the combination of elraglusib with zoldonrasib in vitro resulted in enhanced anti-tumor activity of the combination and greater reductions in tumor cell viability compared with either agent alone.

"Resistance to frontline chemotherapy remains a major challenge in pancreatic cancer, underscoring the need for new therapeutic strategies to be used after patients progress on FOLFIRINOX," said Dr. Deva Mahalingam, Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University. "Across multiple FOLFIRINOX-resistant pancreatic cancer models, we observed greater antitumor activity when elraglusib was combined with zoldonrasib than with either agent alone, with quantitative analysis supporting enhanced anti-tumor activity and potential synergistic interactions of the combination in the models evaluated. These findings provide a compelling rationale to further investigate whether combining GSK-3β (elraglusib) and RAS G12D inhibition can enhance therapeutic activity in treatment-resistant pancreatic cancer. We look forward to participating in advancing the development of elraglusib in upcoming clinical trials, including combination trials with these most promising RAS inhibitors."

Key preclinical findings

Across murine KPC and human PDX-derived pancreatic cancer cell lines, the addition of elraglusib to zoldonrasib reduced cell growth beyond that observed with zoldonrasib alone across all models tested.
Elraglusib in combination with daraxonrasib demonstrated enhanced activity across multiple murine/human PDAC models compared with daraxonrasib alone.
In independent cell line models of FOLFIRINOX-resistant PDAC, both murine and human models of elraglusib plus zoldonrasib produced greater reductions in tumor-cell viability than either agent alone

Additional studies are ongoing, with results planned for presentation at upcoming medical conferences.

"RAS-targeted therapies are rapidly reshaping the treatment landscape for pancreatic cancer, highlighted by the recent FDA approval of daraxonrasib, the first broad RAS-targeted therapy approved for metastatic pancreatic cancer," said Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics. "What is particularly compelling about the synergy data with elraglusib is the breadth and consistency of these findings. Elraglusib enhanced RAS-targeted activity across multiple murine and human models, with two distinct RAS inhibitors, and in models resistant to FOLFIRINOX. We believe these independent findings strengthen the potential for elraglusib to work synergistically with RAS-directed therapies and establish an important new combination approach in pancreatic and potentially other RAS-driven cancers."

(Press release, Actuate Therapeutics, SEP 9, 2026, View Source [SID1234670704])

On September 9, 2026 Crossbow Therapeutics, Inc., a biotechnology company focused on developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, reported dosing of the first participant in its TelOscope-001 Phase 1 clinical trial of CBX-663, a first-in-class T-cell engager (TCE) for the treatment of multiple hematologic and solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CBX-663 is the second candidate developed through Crossbow’s T-Bolt platform, a portfolio of novel TCE molecules that uniquely target peptide human leukocyte antigen (pHLA) complexes on tumor cells, using antibodies that mimic T-cell receptors (TCR-mimetics). The wholly owned TCE is a potent bispecific antibody that targets telomerase reverse transcriptase (TERT), a protein that drives tumor growth and is overexpressed in approximately 90% of all cancers.1,2

"TERT is a priority target for anticancer therapy due to its widespread overexpression, which allows cancer cells to bypass cellular aging, promotes uncontrolled tumor proliferation, and correlates with disease severity," said Briggs Morrison, M.D., Chief Executive Officer of Crossbow Therapeutics. "CBX-663 selectively targets a TERT-derived pHLA complex expressed across a broad range of hematologic and solid malignancies, making it a promising therapeutic candidate in an area of heightened unmet medical need."

The Phase 1, open-label, dose-escalation TelOscope-001 study is evaluating the safety, tolerability, and clinical activity of CBX-663 in patients with relapsed or refractory myeloid malignancies, advanced solid tumors, or recurrent or progressive glioblastoma multiforme (GBM).

CBX-663 binds to TERT-derived pHLA complexes on the surface of tumor cells and activates T cells through a CD3-binding arm, one half of an engineered bispecific antibody designed to grab onto the CD3 protein on T cells. The molecule includes two binding domains for TERT, which increase its ability to engage tumor cells and boost immune activation.

In preclinical studies, CBX-663 drove potent, antigen-specific tumor killing across multiple TERT-positive cancer models, with minimal activity against TERT-negative or HLA-mismatched cells. CBX-663 also demonstrated a favorable safety profile and pharmacokinetics comparable to conventional antibody therapies.

Crossbow discovered and developed CBX-663 through its proprietary T-Bolt platform, which uses optimized antibody libraries and precision screening to find high-affinity, specific binders to intracellular tumor antigens displayed as pHLA complexes. Crossbow designed and is conducting the TelOscope-001 clinical study, which is investigating CBX-663 on a fixed step-up dosing schedule. The company expects initial clinical data from TelOscope-001 around the end of 2027.

For additional trial details, visit the TelOscope-001 (NCT07779798) study page on ClinicalTrials.gov.

(Press release, Crossbow Therapeutics, SEP 9, 2026, View Source [SID1234670702])

On September 9, 2026 InduPro, Inc., a biotechnology company harnessing protein proximity to create novel therapeutics for cancer and autoimmune diseases, reported the publication in Nature of research establishing the spatial organization of cell-surface proteins as a new and therapeutically actionable dimension of disease biology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study, Proximity-Guided Graph Learning Reveals Tumor-Associated Proximity Antigens, describes an integrated approach developed by InduPro to systematically map the nanoscale neighborhoods surrounding proteins on the surface of tumor cells, identify unique disease-associated spatial relationships, and translate those relationships into novel therapeutic strategies. The work defines Tumor-Associated Proximity Antigens, or TAPAs, a new class of co-targets distinguished not simply by protein co-expression, but by their disease-associated spatial proximity to another therapeutically relevant cell-surface antigen.

"By industrializing high-resolution proximity mapping and combining it with computational approaches that allow us to understand protein neighborhoods at scale, we can uncover biology that is invisible to expression-based approaches alone. TAPAs give us a new class of targets and, importantly, a new framework for designing medicines around relationships that are enriched in disease context," said Scott Lesley, Ph.D., President and Chief Scientific Officer of InduPro. "IDP-001, our lead clinical program in squamous and non-squamous solid tumors, is a powerful example of that translation, taking a newly uncovered protein pair and translating it into a highly differentiated therapeutic."

Mapping a previously hidden layer of cell-surface biology

Proteins on the surface of cells exist within organized, dynamic neighborhoods that influence signaling, trafficking and therapeutic response. Yet conventional target-discovery approaches have largely focused on which proteins are present and how they are expressed, leaving this spatial dimension of biology relatively unexplored.

The work builds on protein proximity-based mapping technology invented by Rob Oslund, Ph.D., Vice President of Platform Technology, and Niyi Fadeyi, Ph.D., Vice President of Chemical Sciences, both members of InduPro’s founding team. The technology was subsequently industrialized and expanded at InduPro into a scalable discovery platform.

In the Nature study, researchers applied this approach at scale across diverse tumor systems, creating a rich dataset of cell-surface protein neighborhoods and demonstrating that proximity reveals biological information beyond expression alone.

InduPro subsequently developed MetaMap to move beyond individual proximity maps and extract recurring spatial relationships across large datasets. By integrating proximity signatures across targets and biological contexts, MetaMap reveals protein communities and predicts spatial relationships even when proteins have not been directly mapped against one another. Graph-based machine learning further enables these relationships to be prioritized for therapeutic discovery.

"What began as a technology for labeling proteins within defined nanoscale environments has become something much broader: a way to systematically interrogate the spatial organization of the cell surface," said Rob Oslund, Ph.D., Vice President of Platform Technology at InduPro. "The critical step was industrializing the technology so we could generate these datasets at scale. MetaMap takes that evolution further by allowing us to learn across the collective dataset, moving beyond individual experiments toward a predictive understanding of protein relationships and creating an increasingly powerful foundation for therapeutic discovery."

TAPAs create a new class of therapeutic targets

A central advance described in the publication is the definition of Tumor-Associated Proximity Antigens, or TAPAs.

Rather than defining targets solely by differential expression, TAPAs are identified through disease-associated spatial relationships between proteins on the cell surface. These relationships create opportunities to design multispecific medicines that recognize a disease-associated protein neighborhood rather than relying on either antigen independently.

This approach has the potential to expand the universe of therapeutically actionable targets, including proteins that may not be sufficiently tumor-selective on their own, while creating new opportunities to improve selectivity, internalization and therapeutic activity through proximity-driven drug design.

"TAPAs represent a fundamentally different way to think about therapeutic targets," said Niyi Fadeyi, Ph.D., Vice President of Chemical Sciences at InduPro. "Rather than only asking which proteins are expressed in disease, we can also ask which proteins come together in a disease-specific context and whether that relationship creates a therapeutic opportunity. We believe this opens an important new dimension of target space and provides a foundation for designing medicines with differentiated selectivity and activity. Seeing this concept progress from the original science to therapeutic programs in the clinic provides validation of the approach and what we believe proximity biology can unlock."

Translating Proximity Biology into Medicines

The study demonstrates that proximity-defined relationships can be translated directly into therapeutic design. Using spatial relationships identified through the platform together with biological and translational data, InduPro demonstrated that co-targeting proximity-defined antigen pairs can produce differentiated tumor cell internalization and killing across therapeutic modalities.

These discoveries established the scientific foundation for InduPro’s proximity-guided therapeutic pipeline, including IDP-001, the Company’s lead bispecific antibody-drug conjugate, which has advanced into Phase 1 clinical development.

The progression from proximity-labeling technology, to industrialized spatial datasets, to MetaMap and computational prediction, to TAPAs and ultimately therapeutic candidates represents the broader vision of InduPro’s platform: transforming spatial relationships between proteins into a systematic source of new targets and differentiated medicines.

The article is available in Nature at View Source
(Press release, InduPro, SEP 9, 2026, View Source [SID1234670701])